Halozyme Therapeutics Inc. (NASDAQ:HALO)’s share price was down 1.7% during mid-day trading on Friday . The stock traded as low as $9.76 and last traded at $9.80, with a volume of 628,839 shares changing hands. The stock had previously closed at $9.97.

Several equities analysts recently issued reports on HALO shares. Canaccord Genuity restated a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Jefferies Group reiterated a “sell” rating and set a $6.75 target price on shares of Halozyme Therapeutics in a research report on Tuesday, May 10th. Wells Fargo & Co. reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 8th. Finally, Piper Jaffray Cos. reiterated an “overweight” rating and set a $15.00 target price on shares of Halozyme Therapeutics in a research report on Thursday, June 23rd. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $15.68.

The stock’s market cap is $1.26 billion. The firm has a 50-day moving average of $9.83 and a 200-day moving average of $9.53.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.06. During the same quarter last year, the firm earned $0.02 earnings per share. The firm earned $33.30 million during the quarter, compared to analyst estimates of $29.94 million. Halozyme Therapeutics’s quarterly revenue was down 23.3% on a year-over-year basis. On average, equities analysts anticipate that Halozyme Therapeutics Inc. will post ($0.91) earnings per share for the current year.

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.